You are here: Industry Insights > Bioheng

News List

CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA prnasia
January 29, 2022
Recently, Nanjing Bioheng Biotech Co., Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food...
Professor Carl June, the "Pioneer of CAR-T", Joined Bioheng Scientific Advisory Board prnasia
October 19, 2021
Nanjing Bioheng Biotech Co., Ltd (hereafter Bioheng), announced that Professor Carl June, an authoritative cancer immunologist and "Pioneer of Chimeric Antigen Receptor T (CAR-T) cells...
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL. prnasia
June 21, 2021
Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia.
Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL firstwordpharma
June 21, 2021
Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).
Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting prnasia
November 13, 2020
Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focuses on developing novel cellular immunotherapy, announced that their preliminary data including the pre-clinical development, manufacturing, and investigator initiated trial (IIT) ...